glp 1 and gip for weight loss GLP-1 Drugs: How Semaglutide & Tirzepatide Redefine Obesity Care GLP-1 V2 - Regenics

We examine the role of receptor binding kinetics and -arrestin-biased signaling in the observed trafficking profiles, identifying a linked set of agonist characteristics optimally suited for insulin secretion, not shared by GLP-1R agonists in the current clinical use

This data underscores how Ozempic and other semaglutide drugs can cause real harms to patients

adults are now taking GLP-1 medications, primarily for weight management

Dotson CD, Shaw HL, Mitchell BD, Munger SD, Steinle NI

Funding This study was supported by grants from the Scientific Research Foundation of the Ministry of Education of China (Grant No.2021JH019) and Scientific Research Foundation of Postdoctoral Department of Heilongjiang Province (Grant No.LBH-Q21025)

Sotagliflozin and kidney outcomes, kidney function, and albuminuria in type 2 diabetes and CKD: A secondary analysis of the SCORED trial